Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC)

被引：0
|
作者：
Cho, Byoung Chul [1 ]
Kim, Joo-Hang [1 ]
Villegas, Augusto [2 ]
Frusch, Nicolas [3 ]
Murakami, Shuji [4 ]
Shi, Kelvin [5 ]
Ibrahim, Ramy [5 ]
Ballas, Marc [5 ]
Antonia, Scott J. [6 ]
机构：
[1] Yonsei Univ Hlth Syst, Severance Hosp, Yonsei Canc Ctr, Seoul, South Korea
[2] Canc Specialists North Florida, Jacksonville, FL USA
[3] Ctr Hosp Ardenne, Libramont, Belgium
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan
[5] Astrazeneca, Gaithersburg, MD USA
[6] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; MEDI4736; PD-L1; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-090
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [1] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    de Wit, M.
    Laack, E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S24 - S24
  • [2] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    Laack, H. -E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 186 - 187
  • [3] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NSCLC (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
    Antonia, S.
    Iannotti, N. O.
    Salamat, M. A.
    Krebs, A. D.
    Jayawardene, D.
    Ballas, M.
    Stockman, P. K.
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
    Paz-Ares, L.
    Villegas, A.
    Daniel, D.
    Baz, D. V.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE 3 NSCLC WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
    Creelan, B.
    Iannotti, N. O.
    Salamat, M. A.
    Jayawardene, D.
    Ballas, M.
    Stockman, P. K.
    Antonia, S. J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [6] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
    Schulz, C.
    Laack, E.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270
  • [7] PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Baz, D. Vincente
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (05): : 1314 - 1315
  • [8] A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC
    Nagarkar, R.
    Gascon, P.
    Smakal, M.
    Syrigos, K.
    Barrios, C.
    Cardenas Sanchez, J.
    Zhang, L.
    Tomita, D.
    Park, J.
    Brandao, C. De Oliveira
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S359 - S359
  • [9] A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN
    Wang, Luhua
    Chen, Ming
    Kato, Ken
    Wyrwicz, Lucjan
    Smyth, Elizabeth Catherine
    Jiang, Anastasia
    Zhang, Di
    Robbins, Scott H.
    He, Philip
    Negro, Alejandra
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy
    Dy, Grace K.
    Prasad, Dheerendra
    Kumar, Prasanna
    Attwood, Kristopher
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : E19 - E20
12345